Pipeline
Our Programs
Scioto Biosciences’ leading clinical candidate SB-121 is poised to enter the clinic in 2019.
Our Focus
GI Immaturity in Premature Infants
Annually in the United States there are…
- 60,000 infants with very low birth weight
- 275,000 infants with low birth weight
Premature infants have greater nutritional needs in the neonatal period than at any other time of their lives.There is increasing understanding in the NICU of the importance of infant gut microbiome to overall health.
Immaturity of the preterm infant gut has devastating consequences, including:
- Feeding intolerance
- Late-onset sepsis
- Necrotizing enterocolitis (NEC)
- Long-term consequences such as development disabilities and adverse health outcomes
An FDA-approved, safe, efficacious, single-dose product for preterm infant GI health in the NICU is desperately needed. L. reuteri is widely recognized as an important bacteria in breastmilk. Scioto envisions SB-121 as a universal tool in the NICU for prevention of NEC, sepsis, death, and feeding intolerance in preterm infants.
Immaturity of the preterm infant gut has devastating consequences, including:
- Feeding intolerance
- Late-onset sepsis
- Necrotizing enterocolitis (NEC)
- Long-term consequences such as development disabilities and adverse health outcomes
An FDA-approved, safe, efficacious, single-dose product for preterm infant GI health in the NICU is desperately needed. L. reuteri is widely recognized as an important bacteria in breastmilk. Scioto envisions SB-121 as a universal tool in the NICU for prevention of NEC, sepsis, death, and feeding intolerance in preterm infants.
- Well studied with safety and efficacy proven in over 25 clinical studies (zero adverse events)
- Promotes GI and women’s health
- Serves as a “pioneer” bacteria that promotes GI microbiome development and prevents GI damage
- Remarkable effects on the gut with a single dose
C. difficile infection
Clostridioides difficile, also known as C.diff, is characterized by infectious bacterium that attack the lining of the intestine, causing abdominal pain, diarrhea, fever, increased white blood cell count, and often leads to kidney failure or life-threatening inflammation of the colon.
Within a month of diagnosis, 1 in 11 people over age 65 died of a healthcare-associated C. diff infection.
Our Initial Bacteria with the ABT Platform – SB-121
Lactobacullus reuteri therapeutic from breast milk bacteria